Clinical responses to BCMA- or GPRC5D-directed T-cell engagers in relapsed/refractory multiple myeloma (MM) are often limited by disease relapse and antigen escape, underscoring the need for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results